MSFrontier

Mixed

DHODH inhibition (pyrimidine synthesis): reduce relapses and new lesions in relapsing MS

relapsing MS · DHODH inhibition (pyrimidine synthesis)

Controlled trials disagree.

1 trial(s) stopped for safety reasons.

Trials
10
Running now
3
Controlled phase 2/3 trials
3
People in controlled trials
1545

Deciding trials (phase 3): 1 met, 1 did not.

Other linked trials: 8

Dose comparisons, trials against another medicine, add-on trials, phase 1 and uncontrolled studies. They are listed below but do not set the status.

Trials

  • TERIKIDSdecides the statusMissed main goal

    Phase 3 · 2014 · Placebo-controlled · MSFT-NCT02201108

  • TOWERdecides the statusMet main goal

    Phase 3 · 2008 · Placebo-controlled · MSFT-NCT00751881

Other linked trials: 8

These linked trials do not set the status.

  • Main study: switch sub-study: switch-jcvNo result found

    Phase 4 · 2013 · Not randomised

  • TWINSOngoing

    Phase 3 · 2025 · Not randomised

  • FENhance 2Ongoing

    Phase 3 · 2021 · Compared with teriflunomide

  • FENhanceOngoing

    Phase 3 · 2021 · Compared with teriflunomide

  • TERACLESStopped: safety

    Phase 3 · 2011 · Placebo-controlled

  • TENEREResult was for a different measure

    Phase 3 · 2009 · Compared with interferon beta-1a

  • EMPhASISMet main goal

    Phase 2 · 2019 · Placebo-controlled

  • TREAT-MSResult in a paper, not read yet

    Phase not applicable · 2018 · Not randomised

The deciding phase and counts come from the Trial Bank’s fixed rules.

Lab evidence

Lab studies in animals or cells. Results in animals often do not hold in people, and these studies never change the status of an idea.

Loading lab studies…

Loading reviews and guidelines…

History

  • 2026-10-28Trials: 9 → 10
  • 2026-10-28Status changed from Being tested to Mixed
  • 2026-10-27First listed as Being tested

Related hypotheses

Assembled by software from public sources and not checked by people. Each record links to its source. Report an error